Given the significance of ErbB receptors in human cancers, inhibitors targeting ErbB have been approved for cancer treatment (Hassan & Seno, 2022), such as Cetuximab (Erbitux), which targets EGFR and is used to treat advanced colorectal cancer (Hynes & MacDonald, 2009). This evidence concerns the gene EGFR and cancer.